Garden Life Sciences: Subsidiary obtains drug registration certificate

The Garden Biotech company announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceuticals Co., Ltd., has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for "Ezetimibe and Atorvastatin Calcium Tablets". This drug is mainly used to treat hypercholesterolemia and homozygous familial hypercholesterolemia. According to data from MiNei.com, the market size of Ezetimibe and Atorvastatin Calcium Tablets in public medical institutions is expected to be approximately 56.6 million yuan by 2025. Obtaining the drug registration certificate this time will further enrich the company's product line, promote the upgrading of product construction, and have a positive impact on the company's development.